What does this research mean for the field?

In patients with transthyretin amyloid cardiomyopathy, tafamidis treatment induces an early and sustained increase in transthyretin concentration that independently correlates with reduced all-cause mortality. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To determine the impact of tafamidis on serum transthyretin concentration and evaluate whether early concentration changes at month 1 predict 30-month all-cause mortality.

August 29, 2026Cardiology and TherapyOpen Access

Impact of Tafamidis on Transthyretin Concentration and Its Relation to All-Cause Mortality in Patients with Transthyretin Amyloid Cardiomyopathy: An Analysis from ATTR-ACT

View Full Paper

Ask AI

Bookmark

Authors

MMMathew S. Maurer PEPerry Elliott JKJeffery W. Kelly

Discussion

Member takes

Overview

Randomized trial analysis shows early increases in transthyretin concentration predict lower mortality in transthyretin amyloid cardiomyopathy, indicating a potential prognostic biomarker.

Key Points

To determine the impact of tafamidis on serum transthyretin concentration and evaluate whether early concentration changes at month 1 predict 30-month all-cause mortality.
Post hoc analysis of the phase 3 multicenter randomized trial ATTR-ACT (NCT01994889) in patients with transthyretin amyloid cardiomyopathy receiving tafamidis 80 mg or placebo who survived through month 1.
Evaluated the association between month 1 transthyretin change and 30-month all-cause mortality using logistic regression and univariate and multivariable Cox models adjusted for baseline transthyretin levels and disease stage.
Tafamidis 80 mg increased mean transthyretin by 36.3% (mean [SD] change 7.3 [3.9] mg/dL) at month 1 with sustained elevation through month 30, whereas placebo showed minimal change (-0.02 [2.9] mg/dL).
Each 5 mg/dL increase in month 1 transthyretin was associated with a 45.0% reduction in odds of all-cause mortality by month 30 in tafamidis-treated patients (p = 0.0193).
Every 1 mg/dL increase in early transthyretin was associated with a 9.3% reduction in mortality hazard (HR 0.907; 95% CI 0.837–0.983; p = 0.0174) in univariate analysis, and an 8.7% hazard reduction in multivariable analysis.

Cite This Study

Maurer et al. (2026) studied this question.

synapsesocial.com/papers/6a9299bb8e5d7d1fc0c11dad https://doi.org/10.1007/s40119-026-00468-2

View Full Paper

Ask AI

Bookmark

August 29, 2026Cardiology and TherapyOpen Access

Impact of Tafamidis on Transthyretin Concentration and Its Relation to All-Cause Mortality in Patients with Transthyretin Amyloid Cardiomyopathy: An Analysis from ATTR-ACT

View Full Paper

Ask AI

Bookmark

Authors

MMMathew S. Maurer PEPerry Elliott JKJeffery W. Kelly

Discussion

Member takes

Overview

Randomized trial analysis shows early increases in transthyretin concentration predict lower mortality in transthyretin amyloid cardiomyopathy, indicating a potential prognostic biomarker.

Key Points

To determine the impact of tafamidis on serum transthyretin concentration and evaluate whether early concentration changes at month 1 predict 30-month all-cause mortality.
Post hoc analysis of the phase 3 multicenter randomized trial ATTR-ACT (NCT01994889) in patients with transthyretin amyloid cardiomyopathy receiving tafamidis 80 mg or placebo who survived through month 1.
Evaluated the association between month 1 transthyretin change and 30-month all-cause mortality using logistic regression and univariate and multivariable Cox models adjusted for baseline transthyretin levels and disease stage.
Tafamidis 80 mg increased mean transthyretin by 36.3% (mean [SD] change 7.3 [3.9] mg/dL) at month 1 with sustained elevation through month 30, whereas placebo showed minimal change (-0.02 [2.9] mg/dL).
Each 5 mg/dL increase in month 1 transthyretin was associated with a 45.0% reduction in odds of all-cause mortality by month 30 in tafamidis-treated patients (p = 0.0193).
Every 1 mg/dL increase in early transthyretin was associated with a 9.3% reduction in mortality hazard (HR 0.907; 95% CI 0.837–0.983; p = 0.0174) in univariate analysis, and an 8.7% hazard reduction in multivariable analysis.

Cite This Study

Maurer et al. (2026) studied this question.

synapsesocial.com/papers/6a9299bb8e5d7d1fc0c11dad https://doi.org/10.1007/s40119-026-00468-2

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark